Allergan urges shareholders to reject Valeant Pharmaceuticals takeover offer
MONTREAL - Allergan Inc. urged its shareholders Monday to reject a hostile takeover offer by Valeant Pharmaceuticals International Inc. (TSX:VRX) in the latest step in the bitter fight between the companies.
Allergan called the offer grossly inadequate and said it created significant risks and uncertainties for Allergan shareholders.
Valeant, which had tried to negotiate a deal to acquire Allergan, took its offer directly to the company's shareholders last week.
The company has offered US$72 in cash plus 0.83 of a Valeant share for each share of the Botox maker.
The bid values Allergan at more than US$50 billion.
The recommendation is the latest step in the takeover fight which threatens to become a prolonged battle.
Bill Ackman's Pershing Square Capital Management, which is backing the Valeant offer, is also seeking to call a special meeting of Allergan's shareholders to remove six directors.
Pershing owns 9.7 per cent of Allergan.
Read more Business News
- 102nd birthday boat cruiseKelowna
- Fundraising effort with a twistKelowna
- Burning pole cuts powerWest Kelowna
- Search on for missing manWest Kelowna
|QHR Technologies Inc||1.19||0.00|
|Anavex Life Sciences||0.24||0.00|
|Copper Mountain Mining||2.91||-0.05|
|Sunrise Resources Ltd||0.025||0.00|
|Mission Ready Services||0.25||+0.01|
There are several things to consider when deciding how much home to buy. 1. Draw up a budget including the new mortgage payments. While the rules used by most lenders require that the mortgage paym...
Photo: ContributedI would call it a joy ride... You see a planned project or business has a destination. It may be an ongoing revenue stream, it may be a business value or an exit strategy. If you don...
Establishing a joint account may seem like a great strategy at first glance. However, there are many factors that must be considered before taking this action. This article will explore the use of &ls...